ArticleInternational immunology2009
A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation.
Article in International immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 59 citations in OpenAlex.
- CXCL12+ dermal fibroblasts promote neutrophil recruitment and host defense by recognition of IL-17.The Journal of experimental medicine · 2024Article
- The Protective Effect of a Functional Food Consisting ofFoods (Basel, Switzerland) · 2023Article
- Regulation of Peripheral Inflammation by a Non-Viable, Non-Colonizing Strain of Commensal Bacteria.Frontiers in immunology · 2022Article
- Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.Nature reviews. Drug discovery · 2022Review
- Article
- New and Emerging Therapies for Pediatric Atopic Dermatitis.Paediatric drugs · 2019Article
- JNJ7777120 Ameliorates Inflammatory and Oxidative Manifestations in a Murine Model of Contact Hypersensitivity via Modulation of TLR and Nrf2 Signaling.Inflammation · 2018Article
- Article
- The therapeutic potential of CRTH2/DP2 beyond allergy and asthma.Prostaglandins & other lipid mediators · 2017Review
- A CCR2+ myeloid cell niche required for pancreatic β cell growth.JCI insight · 2017Article
- The importance of TSLP in allergic disease and its role as a potential therapeutic target.Expert review of clinical immunology · 2014Review
- Role of prostaglandin D2 /CRTH2 pathway on asthma exacerbation induced by Aspergillus fumigatus.Immunology · 2014Article
- T-helper type-2 contact hypersensitivity of Balb/c mice aggravated by dibutyl phthalate via long-term dermal exposure.PloS one · 2014Article
- The CRTH2 agonist Pyl A prevents lipopolysaccharide-induced fetal death but induces preterm labour.Immunology · 2013Article
- Cutting edge: allergen-specific CD4 T cells respond indirectly to thymic stromal lymphopoietin to promote allergic responses in the skin.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- The biology of thymic stromal lymphopoietin (TSLP).Advances in pharmacology (San Diego, Calif.) · 2013Review
- Thymic stromal lymphopoietin and allergic disease.The Journal of allergy and clinical immunology · 2012Review
- The multiple facets of thymic stromal lymphopoietin (TSLP) during allergic inflammation and beyond.Journal of leukocyte biology · 2012Review
- Optimization of the Central Core of Indolinone-Acetic Acid-Based CRTH2 (DP2) Receptor Antagonists.ACS medicinal chemistry letters · 2011Article
- Dual functions of prostaglandin D2 in murine contact hypersensitivity via DP and CRTH2.The American journal of pathology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
A FITC-induced allergic contact hypersensitivity model was used to investigate the role that the prostaglandin D(2) receptor-chemoattractant receptor-homologous molecule expressed on T(h)2 cells (CRTH2) plays in modulating cutaneous inflammation. Our results show that inhibition of CRTH2, achieved via administration of a potent, small molecule antagonist, Compound A (Cmpd A), effectively blocked edema formation and greatly reduced the inflammatory infiltrate and skin pathology observed in drug vehicle-treated animals. Gene expression analysis revealed that Cmpd A administration down-regulated the transcription of a wide range of pro-inflammatory mediators. This correlated with decreases in cytokine and chemokine protein levels, notably IL-4, IL-1beta, tumor necrosis factor-alpha, transforming growth factor-beta, GRO-alpha, MIP-2 and thymic stromal lymphopoietin (TSLP) in FITC-challenged ears. The administration of an anti-TSLP-neutralizing antibody was only partially effective in lowering the FITC-induced inflammatory infiltrate and cytokine production compared with the CRTH2 antagonist. Taken together, these data suggest that blockade of CRTH2 inhibits multiple pathways leading to cutaneous inflammation in this model. This suggests that CRTH2 antagonism may be a viable route for therapeutic intervention in allergic skin diseases, such as atopic dermatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.